Pre-made Itepekimab benchmark antibody ( Whole mAb, anti-IL33 therapeutic antibody, Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-283

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-283 Category Tag

Product Details

Pre-Made Itepekimab biosimilar, Whole mAb, Anti-IL33 Antibody: Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Itepekimab is an anti-interleukin-33 (IL-33) monoclonal antibody being developed by Sanofi, in collaboration with Regeneron Pharmaceuticals, for the treatment.

Products Name (INN Index)

Pre-Made Itepekimab biosimilar, Whole mAb, Anti-IL33 Antibody: Anti-C9orf26/DVS27/IL1F11/NF-HEV/NFEHEV therapeutic antibody

INN Name

Itepekimab

Target

IL33

Format

Whole mAb

Derivation

NA

Species Reactivity

Human

CH1 Isotype

IgG4

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-III

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2019

Companies

Regeneron Pharmaceuticals,Sanofi

Conditions Approved

NA

Conditions Active

Chronic obstructive pulmonary disease

Conditions Discontinued

Allergic asthma,Inflammation,Asthma,Atopic dermatitis

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

IL33

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide